APP and Alzheimer disease: Moreover, overexpression of non-Aβ-producing APP fragments could lead to non-physiological interactions with endogenous proteins, potentially adding further to the variability within and amongst the many transgenic models used for AD studies (Jucker and Walker, 2013).